Trial Profile
Phase II Study of Targeting CD28 in Multiple Myeloma With Abatacept (CTLA4-Ig) to Overcome Resistance to Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Abatacept (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 04 Feb 2024 Planned End Date changed from 11 Jan 2024 to 11 Jan 2025.
- 13 Nov 2023 Planned End Date changed from 11 Nov 2023 to 11 Jan 2024.
- 13 Nov 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Jan 2024.